Summary: A novel, large-scale remote study has launched to investigate cybersickness — a common barrier to virtual reality (VR) adoption. Cybersickness arises from a sensory-motor conflict: the headset’s convincing visual motion signals movement while the user’s body remains physically still, producing symptoms such as nausea, dizziness, and discomfort.
To scale beyond the limitations of traditional laboratory research, investigators are using the Virtual Experience Research Accelerator (VERA), a National Science Foundation (NSF)-funded platform that runs standardized VR experiments remotely. By delivering a controlled digital protocol directly to participants’ home headsets, VERA enables rapid collection of rich experimental data at a scale and speed that would be impractical in localized, in-person labs.
Key Facts
- Scaling breakthrough: VERA collected full-study data from more than 250 remote participants in only 15 cumulative days — including over 90 participants in the first 72 hours — far surpassing the original lab study that enrolled just 30 people.
- “Cybersicker” protocol: Each participant completes an approximately 30-minute immersive session on their own Meta Quest headset. The experience features a controlled virtual carnival ride designed to provoke and measure motion-related symptoms.
- Granular measurements: The automated protocol gathers subjective sickness ratings every 30 seconds and records continuous head-tracking coordinates, in-VR visual acuity checks, and pre- and post-exposure questionnaires for a multi-dimensional dataset.
- Target cohort: Enrollment is ongoing with a goal of 2,000 remote participants to capture broad individual variability in cybersickness susceptibility across diverse users.
- Cross-sector impact: Understanding and mitigating the sensory mismatches that cause cybersickness is essential to expanding safe VR use in healthcare, education, workforce training, and general digital accessibility.
Source: UCF
Overview
The first large-scale remote research study of cybersickness using the VERA platform is underway at the University of Central Florida (UCF). Led by Gerd Bruder and a team of university collaborators and external partners, the trial explores who is most susceptible to cybersickness and how symptoms develop over time in real-world home settings.
Early deployment demonstrates VERA’s ability to accelerate VR research. In just a short period, hundreds of participants ran a standardized protocol from home, each completing the remote session on a personal Meta Quest headset. This speed of recruitment and automated data capture highlights how remote platforms can transform experimental reach for immersive technology research.
Compared with conventional lab-based studies — which often take months to enroll and test hundreds of participants — the VERA approach compresses timelines while preserving experimental control. That combination of scale, speed, and data fidelity allows researchers to investigate how demographic, physiological, and behavioral differences influence cybersickness risk.
Preliminary analyses already reveal substantial individual variability in how quickly and severely participants experience symptoms. As enrollment continues toward the 2,000-participant goal, investigators expect to identify patterns and predictors of susceptibility that can guide engineering, design, and clinical strategies to reduce cybersickness.
“Understanding who is susceptible to cybersickness is critical to improving VR accessibility and enabling broader adoption across research, education, and industry,” says Gerd Bruder. Gregory Welch, VERA’s lead principal investigator at UCF, adds: “VERA was built to study problems like this with a combination of speed, scale, and experimental complexity not previously possible. The potential impact spans healthcare, workforce training, accessibility, and learning.”
Key Questions Answered:
A: Cybersickness is driven by a sensory mismatch, often described as a “prediction error” in the brain’s spatial orientation systems. VR visuals can signal rapid motion to the visual system, while the vestibular organs and proprioceptors indicate the body is stationary. That conflict commonly produces nausea, dizziness, and general discomfort.
A: VERA turns consumer VR headsets into remote research devices by delivering a standardized app-based protocol to participants’ Meta Quest headsets. The platform controls the session, prompts symptom ratings at 30-second intervals, runs visual acuity checks inside VR, and records continuous head-tracking data that streams back to the research team for analysis.
A: Small lab studies often cannot represent the full diversity of human physiology and behavior. A large, diverse sample lets researchers detect meaningful subgroups, biological risk factors, and resilience patterns. Those insights enable engineers and designers to create adaptive software filters, accessibility modes, and safer hardware standards tailored to varied user needs across healthcare, training, and education.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The referenced journal paper was reviewed in full.
- Additional context was added by staff.
About this cybersickness and neurotech research news
Author: Mikita Nayee
Source: UCF
Contact: Mikita Nayee – UCF
Image: The image is credited to Neuroscience News